Next Article in Journal
Gelsolin Contributes to the Motility of A375 Melanoma Cells and This Activity Is Mediated by the Fibrous Extracellular Matrix Protein Profile
Next Article in Special Issue
Invadopodia, a Kingdom of Non-Receptor Tyrosine Kinases
Previous Article in Journal
Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice
Previous Article in Special Issue
SUN-MKL1 Crosstalk Regulates Nuclear Deformation and Fast Motility of Breast Carcinoma Cells in Fibrillar ECM Microenvironment

Are We Ready for Migrastatics?

Cell Migration and Invasion Laboratory, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel
Laboratory of Cancer Cell Invasion, Department of Cell Biology, Charles University, Viničná 7, 128 44 Prague, Czech Republic
Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Faculties of Charles University, Průmyslová 595, 252 42 Vestec u Prahy, Czech Republic
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Matthias Buck
Cells 2021, 10(8), 1845;
Received: 27 June 2021 / Revised: 16 July 2021 / Accepted: 18 July 2021 / Published: 21 July 2021
(This article belongs to the Special Issue Molecular, Cellular and Therapeutic Approaches to Cancer Metastasis)
Metastasis accounts for the highest mortality rates in solid tumor cancer patients. However, research and development have neglected this most lethal characteristic and, instead, have concentrated on the hallmarks of cancer that make tumor cells highly proliferative and distinctive from nonmalignant cells. The concentration on invasion and metastasis can be one of the most meaningful advancements in cancer investigation. Importantly, metastasis-free survival (MFS) was recently approved by the Food and Drug Administration (FDA) as a novel primary endpoint in clinical trials and has been used to evaluate the prognosis of patients with nonmetastatic castration-resistant prostate cancer and soft tissue sarcoma. This new definition enables to shift the focus of research and development in cancer therapeutics toward metastasis and to change the emphasis from using tumor shrinkage as a benchmark for indicating the efficacy of treatment to using MFS as a more representative endpoint for antimetastatic drugs. This perspective outlines the possibility to use this novel endpoint in other solid cancers, and examples of large clinical trials are given in which MFS is defined as an endpoint and/or in which antimetastatic strategies are being examined. These advances now open the door for the rapid development of antimetastatic therapies, which could be used in combination with standard cytotoxic cancer therapies. With pioneer research on metastasis prevention on the rise and the underlying biomechanisms of tumor cell motility and invasion explored further than ever before, we believe an intensified focus on antimetastatic properties will shape this era of cancer translational research. View Full-Text
Keywords: cancer metastasis; clinical trials; metastasis-free survival; metastasis inhibitor; research and development cancer metastasis; clinical trials; metastasis-free survival; metastasis inhibitor; research and development
MDPI and ACS Style

Solomon, J.; Raškova, M.; Rösel, D.; Brábek, J.; Gil-Henn, H. Are We Ready for Migrastatics? Cells 2021, 10, 1845.

AMA Style

Solomon J, Raškova M, Rösel D, Brábek J, Gil-Henn H. Are We Ready for Migrastatics? Cells. 2021; 10(8):1845.

Chicago/Turabian Style

Solomon, Jonathan, Magdalena Raškova, Daniel Rösel, Jan Brábek, and Hava Gil-Henn. 2021. "Are We Ready for Migrastatics?" Cells 10, no. 8: 1845.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop